Amneal Pharmaceuticals Inc (NYSE:AMRX) Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC lowered its position in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 9.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 25,937 shares of the company’s stock after selling 2,676 shares during the quarter. Hsbc Holdings PLC’s holdings in Amneal Pharmaceuticals were worth $350,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently bought and sold shares of AMRX. Renaissance Technologies LLC bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $8,448,000. BlackRock Inc. raised its holdings in shares of Amneal Pharmaceuticals by 2.1% in the 3rd quarter. BlackRock Inc. now owns 5,931,927 shares of the company’s stock worth $131,629,000 after purchasing an additional 123,844 shares during the period. Jane Street Group LLC bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $249,000. Swiss National Bank raised its holdings in shares of Amneal Pharmaceuticals by 48.2% in the 3rd quarter. Swiss National Bank now owns 182,100 shares of the company’s stock worth $4,041,000 after purchasing an additional 59,200 shares during the period. Finally, Legal & General Group Plc raised its holdings in shares of Amneal Pharmaceuticals by 20.7% in the 3rd quarter. Legal & General Group Plc now owns 32,695 shares of the company’s stock worth $726,000 after purchasing an additional 5,596 shares during the period. 38.92% of the stock is currently owned by hedge funds and other institutional investors.

Shares of AMRX traded up $0.19 during mid-day trading on Friday, reaching $12.70. 1,149,088 shares of the stock traded hands, compared to its average volume of 727,021. The firm has a market capitalization of $3.79 billion, a P/E ratio of 13.37, a price-to-earnings-growth ratio of 0.58 and a beta of 1.38. The company has a debt-to-equity ratio of 2.98, a current ratio of 2.32 and a quick ratio of 1.50. Amneal Pharmaceuticals Inc has a 1 year low of $11.63 and a 1 year high of $24.48.

Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings data on Thursday, February 28th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.06. Amneal Pharmaceuticals had a net margin of 1.84% and a return on equity of 25.73%. The company had revenue of $497.53 million during the quarter, compared to the consensus estimate of $478.06 million. On average, analysts expect that Amneal Pharmaceuticals Inc will post 0.97 earnings per share for the current year.

A number of equities research analysts recently commented on the stock. ValuEngine lowered shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, January 10th. Zacks Investment Research lowered shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, January 14th. SunTrust Banks assumed coverage on shares of Amneal Pharmaceuticals in a research note on Tuesday, March 19th. They issued a “buy” rating and a $16.00 price objective for the company. Leerink Swann lowered shares of Amneal Pharmaceuticals to a “market perform” rating in a research note on Friday, March 8th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $35.00 price objective on shares of Amneal Pharmaceuticals in a research note on Thursday, February 28th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $20.80.

In related news, insider Paul Bisaro acquired 17,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was bought at an average cost of $11.97 per share, with a total value of $203,490.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Peter R. Terreri sold 23,345 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $12.39, for a total transaction of $289,244.55. The disclosure for this sale can be found here. Insiders own 26.34% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Amneal Pharmaceuticals Inc (NYSE:AMRX) Shares Sold by Hsbc Holdings PLC” was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/hsbc-holdings-plc-sells-2676-shares-of-amneal-pharmaceuticals-inc-amrx.html.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Recommended Story: Understanding Market Liquidity

Institutional Ownership by Quarter for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.